Products

Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel

China Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel, Find details about China Cabazitaxel, Anti-Cancer Cabazitaxel from Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel

Model NO.
D-Sung Cabazitaxel
Product Name
Cabazitaxel
Name
Cabazitaxel Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
183133-96-2
Molecular Formula
C45h57no14
Boling Point
870.7-65.0 (Predicted)
Density
1.31
Storage
Cool Dry Place
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Model NO.
D-Sung Cabazitaxel
Product Name
Cabazitaxel
Name
Cabazitaxel Powder
Appearance
White Powder
Color
White
Grade
Pharmaceutical Grade
Assay
HPLC 99%
Application
Anthelmintics
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
183133-96-2
Molecular Formula
C45h57no14
Boling Point
870.7-65.0 (Predicted)
Density
1.31
Storage
Cool Dry Place
Trademark
D-Sung
Transport Package
Negotiable
Specification
99%
Origin
Xi′an Shaanxi
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel
Product NameCabazitaxel
Assay99%
Test MethodHPLC
AppearanceWhite Powder
CAS NO183133-96-2
Molecular FormulaC45H57NO14
Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.

Cabazitaxel in combination is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.

Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelCabazitaxel's anti-cancer mechanism and characteristics are similar to docetaxel and belong to anti-microtubule drugs. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer CabazitaxelPharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel

You Might Also Like